Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients.
Adult
Aged
Alleles
Antiviral Agents
/ pharmacology
Female
Genetic Predisposition to Disease
Genotype
Hepatitis B
/ drug therapy
Hepatitis B virus
/ drug effects
Humans
Interferon-alpha
/ pharmacology
Lipase
/ genetics
Male
Membrane Proteins
/ genetics
Middle Aged
Non-alcoholic Fatty Liver Disease
/ etiology
Polyethylene Glycols
/ pharmacology
Polymorphism, Single Nucleotide
Recombinant Proteins
/ pharmacology
Tolloid-Like Metalloproteinases
/ genetics
Treatment Outcome
HBs antigen
hepatic steatosis
sequential therapy
single nucleotide polymorphism
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Apr 2020
27 Apr 2020
Historique:
received:
24
03
2020
revised:
22
04
2020
accepted:
24
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Lifestyle changes have led to an increase in the number of patients with nonalcoholic fatty liver disease (NAFLD). However, the effects of NAFLD-associated single-nucleotide gene polymorphisms (SNPs) in HBV-infected patients have not been adequately investigated. Methods: We investigated the association of the NAFLD-related SNPs patatin-like phospholipase domain-containing protein 3 (PNPLA3; rs738409), transmembrane 6 superfamily member 2 (TM6SF2; rs58542926), 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13; rs72613567, rs6834314 and rs62305723), membrane-bound O-acyltransferase domain containing 7 (MBOAT7; rs641738) and glucokinase regulatory protein (GCKR; rs1260326) with the presence of histologically proven hepatic steatosis (HS) in HBV-infected patients (
Identifiants
pubmed: 32349377
pii: ijms21093089
doi: 10.3390/ijms21093089
pmc: PMC7247697
pii:
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Membrane Proteins
0
Recombinant Proteins
0
Polyethylene Glycols
3WJQ0SDW1A
Lipase
EC 3.1.1.3
adiponutrin, human
EC 3.1.1.3
Tolloid-Like Metalloproteinases
EC 3.4.-
TLL1 protein, human
EC 3.4.24.-
peginterferon alfa-2a
Q46947FE7K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP17fk0210306
Organisme : Japan Agency for Medical Research and Development
ID : JP19fk0210034
Déclaration de conflit d'intérêts
Shuhei Nishiguchi received research grants from Chugai Pharmaceutical and lecture fees from Gilead Sciences. The remaining authors declare no conflicts of interest in association with the present study.
Références
J Hepatol. 2018 Feb;68(2):268-279
pubmed: 29122391
Gastroenterol Res Pract. 2017;2017:1096406
pubmed: 28421108
Hepatology. 2020 Feb;71(2):539-548
pubmed: 31309589
N Engl J Med. 2018 Mar 22;378(12):1096-1106
pubmed: 29562163
Int J Mol Sci. 2016 May 25;17(6):
pubmed: 27231906
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Liver Int. 2015 Feb;35(2):438-47
pubmed: 25284145
J Gastroenterol. 2014 Aug;49(8):1253-63
pubmed: 24065124
Dig Dis Sci. 2015 Oct;60(10):3005-10
pubmed: 25986529
Hepatology. 2019 Apr;69(4):1504-1519
pubmed: 30415504
Aliment Pharmacol Ther. 2014 May;39(10):1059-70
pubmed: 24654629
J Hepatol. 2014 Nov;61(1 Suppl):S69-78
pubmed: 25443347
J Gastroenterol. 2018 Mar;53(3):438-448
pubmed: 28744823
Medicine (Baltimore). 2016 Apr;95(17):e3565
pubmed: 27124068
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Hepatology. 2020 Jan;71(1):56-66
pubmed: 31155741
Hepatology. 2013 Oct;58(4):1245-52
pubmed: 23564580
Hepatol Res. 2018 May;48(6):459-468
pubmed: 29314465
J Gastroenterol Hepatol. 2018 Jan;33(1):70-85
pubmed: 28670712
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
PLoS One. 2018 Jul 17;13(7):e0199198
pubmed: 30016335
J Viral Hepat. 2013 Feb;20(2):77-84
pubmed: 23301542
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Gastroenterology. 2017 May;152(6):1383-1394
pubmed: 28163062
Gastroenterology. 2012 May;142(5):1140-1149.e3; quiz e13-4
pubmed: 22333950
J Gastroenterol. 2018 Feb;53(2):181-196
pubmed: 29177681
J Viral Hepat. 2019 Oct;26(10):1233-1236
pubmed: 31177595
J Gastroenterol. 2018 Feb;53(2):247-257
pubmed: 28634723
J Gastroenterol. 2019 Apr;54(4):339-346
pubmed: 30382363
Gastroenterology. 2012 Mar;142(3):513-520.e1
pubmed: 22108195
J Hepatol. 2014 Oct;61(4):785-91
pubmed: 24911461
J Gastroenterol Hepatol. 2015 Jan;30(1):14-20
pubmed: 25092429
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Gastroenterol. 2019 Dec;54(12):1096-1105
pubmed: 31134334
J Gene Med. 2018 Jan;20(1):
pubmed: 29218813